DNA methylation is an indispensible epigenetic modification required for regulating the expression of mammalian genomes. Immunoprecipitation-based methods for DNA methylome analysis are rapidly shifting the bottleneck in this field from data generation to data analysis, necessitating the development of better analytical tools. In particular, an inability to estimate absolute methylation levels remains a major analytical difficulty associated with immunoprecipitationbased DNA methylation profiling. To address this issue, we developed a cross-platform algorithm-Bayesian tool for methylation analysis (Batman)-for analyzing methylated DNA immunoprecipitation (MeDIP) profiles generated using oligonucleotide arrays (MeDIP-chip) or next-generation sequencing (MeDIP-seq). We developed the latter approach to provide a high-resolution whole-genome DNA methylation profile (DNA methylome) of a mammalian genome. Strong correlation of our data, obtained using mature human spermatozoa, with those obtained using bisulfite sequencing suggest that combining MeDIP-seq or MeDIP-chip with Batman provides a robust, quantitative and cost-effective functional genomic strategy for elucidating the function of DNA methylation.
Modulation of the epigenome-the combination of DNA-and chromatin-associated epigenetic modifications that exist within a cell-is one of the key mechanisms by which cells generate functional diversity from an essentially static genome 1 . The epigenome is a dynamic entity influenced by predetermined genetic programs or external environmental cues. Given the diversity of cell types within complex organisms such as mammals, it is staggering to think of how many epigenomes exist, or are possible, and unraveling this complexity remains an important challenge.
DNA methylation is the only known epigenetic system that modifies the DNA molecule itself. In mammals, it occurs predominantly at CpG dinucleotides and is involved in diverse processes such as development, genomic integrity, X-inactivation and imprinting 2 . Furthermore, perturbed DNA methyation is a hallmark of several human diseases, including cancer. Consequently, there is great interest in experimental and analytical tools for genome-wide (that is, a limited number of genomic sites that are representative of the genome) or whole-genome DNA methylation profiling. In the last few years, a variety of experimental approaches have emerged for genome-wide, and very recently whole-genome, DNA methylation profiling (reviewed in ref. 3 ). These can be classified into three main categories. The first of these, restriction enzyme-based methods, uses one or more enzymes that restrict DNA only if it is unmethylated (e.g., HpaII or NotI) or methylated (e.g., McrBC). These methods, coupled with either microarrays [4] [5] [6] [7] [8] [9] [10] or capillary sequencing 11 , have been applied to genome-wide DNA methylation profiling of several organisms but are limited to the analysis of CpG sites located within the enzyme recognition site(s). The second group of techniques is based on the reaction between genomic DNA and sodium bisulfite, which converts unmethylated cytosines to uracil (and eventually thymine following amplification), while leaving methylated cytosines unconverted 12 . Bisulfite conversion-based approaches offer single CpG resolution and have been applied to microarrays [13] [14] [15] [16] , high-throughput PCR sequencing 17, 18 and, more recently, to next-generation bisulfite sequencing (BS-seq) 19 , resulting in an almost complete DNA methylation profile (DNA methylome) for the B120-Mb genome of Arabidopsis thaliana. However, the reduction of sequence complexity following bisulfite conversion means that it is difficult to design enough unique probes to analyze bisulfite-converted DNA comprehensively on a genome-wide scale on microarrays, whereas the BS-seq approach is currently prohibitively expensive for the routine analysis of large genomes such as human. Methods of the third class use either 5-methylcytosine-specific antibodies (methylated DNA immunoprecipitation 20 , MeDIP or mDIP 21 ) or methyl-binding domain proteins [22] [23] [24] to enrich for the methylated (or unmethylated 25 ) fraction of the genome by immunopreciptation. MeDIP/mDIP, combined with microarrays (MeDIP-chip), was used to delineate the first high-resolution whole-genome DNA methylation profile of any genome (Arabidopsis 22, 26 ) and the first highresolution DNA methylation profile of human promoters 27 . However, until now, it has not been possible to estimate absolute methylation levels from MeDIP, and analysis of regions with low CpG density has been assumed to be problematic 27 .
Although no single experimental method offers the 'perfect solution' , MeDIP-chip has quickly become a widely used [20] [21] [22] [26] [27] [28] [29] [30] [31] and cost-effective approach for genome-wide and/ or whole-genome DNA methylation analysis. Here, we report the development of a crossplatform algorithm-Batman-that can estimate absolute DNA methylation levels, across a wide range of CpG densities, from MeDIPbased experiments. We first demonstrate Batman's performance on MeDIP-chip, and then show it can also be used to analyze MeDIP profiles generated from next-generation sequencing-a technique we called MeDIP-seq, described here. Our MeDIP-seq data represent a high-resolution whole-genome DNA methylation profile of a mammalian genome, which to our knowledge has not been done before. Batman is a crossplatform analytical tool for data generated from microarrays or next-generation sequencing and will aid future studies aiming to understand the role of DNA methylation in the wider context of the epigenome.
RESULTS

Generation of human genome-wide MeDIP-chip data
MeDIP was performed on three biological replicates of mature spermatozoa from normal human donors (Supplementary Table 1 online) using a modified version of the original MeDIP protocol 20 ( Supplementary Figs. 1 and 2 online) . Human spermatozoa are relatively homogenous, easily obtained and of interest from the point of view of understanding the role of DNA methylation during gametogenesis, fertilization and early embryogenesis. After MeDIP, samples were hybridized to custom high-density oligonucleotide microarrays (Nimblegen Systems) that contained 42,144 regions of interest (ROIs), each typically 500-1,000 bp in length, containing 5-10 unique 50-mer probes. The ROIs overlapped 82% of all known transcriptional start sites (TSSs), 72% of nonpromoter CpG islands and a number of exonic, intronic and intergenic regions in the human genome (Ensembl genome browser 32 , Homo sapiens release 45.36 g, NCBI36). The correlation coeffecients (Pearson's) ranged from 0.54 to 0.72 among the three biological replicates and 0.82 between a pair of technical replicates (dye swaps), suggesting our MeDIP-chip experiments were reproducible.
Bayesian tool for methylation analysis (Batman)
The efficiency of immunoprecipitation in MeDIP depends on the density of methylated CpG sites, which vary greatly within any given mammalian genome, making it difficult to distinguish variations in enrichment from confounding CpG density effects 27 . Consequently, until now, it has been impossible to estimate absolute methylation levels from MeDIP experiments, and the analysis of CpG-poor regions, in particular, has been assumed to be difficult 27 . Therefore, to analyze our MeDIP-chip data, we developed a new algorithm that models the effect of varying densities of methylated CpGs on MeDIP enrichment. This transforms normalized MeDIP-chip log 2 -ratios into a quantitative measure of DNA methylation across a wide range of CpG densities. Our algorithm, Batman, is implemented as a suite of Java scripts (freely available from http://td-blade.gurdon.cam.ac.uk/ software/batman/ under the GNU Lesser General Public License).
Batman relies on the knowledge that almost all DNA methylation in mammals occurs at CpG dinucleotides and, consequently, generates methylation estimates in this context only. We define the coupling factor, C cp , between probe p and CpG dinucleotide c as the fraction of DNA molecules hybridizing to probe p that contain the CpG c. As we know the approximate range of DNA fragment sizes used in the MeDIP experiment (typically 400-700 bp) and assume that there are no fragment-length biases, this is simply a function of the distance between the probe's genomic location and the CpG dinucleotide. This can be estimated empirically by sampling from the fragment-length distribution and randomly placing each fragment such that it overlaps the probe. The resulting distribution is shown in Figure 1a . For a given probe, the sum of coupling factors, which we call C tot , gives a measure of local CpG density. Plotting this parameter against the normalized log 2 -ratios from a typical MeDIP-chip experiment shows a fairly complex relationship (Fig. 1b) . However, consistent with the fact that most CpG-poor regions are methylated, whereas the regions richest in CpG motifs (CpG islands) are generally unmethylated, focusing on the low-CpG portion of this plot reveals an approximately linear relationship between the MeDIP-chip output and the density of methylated CpGs as measured by C tot . Based on this observation, and assuming that only methylated CpGs contribute to the observed signal, we developed a model whereby the signal observed at each array probe should depend on the methylation states of all nearby CpGs, weighted by the coupling factors between those CpGs and the probe. If we let m c indicate the methylation state at position c, and assume that the errors on the microarray are normally distributed with precision, then we can write a probability distribution for a complete set of array observations, A, given a set of methylation states, m, as:
where G (x|m, s 2 ) is a Gaussian probability density function. We can now use any standard Bayesian inference approach to find f(m|A), the posterior distribution of the methylation state parameters given the array (MeDIP-chip) data, and thus generate quantitative methylation profile information.
To reduce the computational cost of analyzing regions with very high CpG density, we took advantage of the fact that CpG methylation state is generally very highly correlated over a scale of hundreds of A N A L Y S I S bases 18 . Instead of modeling every CpG individually, we grouped together all CpGs in 50-or 100-bp windows and assumed that they would have the same methylation state. Inferring the methylation status at each CpG is now a deconvolution problem somewhat analogous to that considered when analyzing chromatin immunoprecipitation data 33 . Standard Bayesian techniques can be used to infer f(m|A), that is, the distribution of likely methylation states given one or more sets of MeDIP-chip outputs. Our implementation of the Batman model uses nested sampling (http://www.inference.phy.cam. ac.uk/bayesys/), a highly robust Monte Carlo technique, to solve this inference problem. For each tiled region of the genome, we used a nested sampler-based approach to generate 100 independent samples from f(m|A). We then summarized the most likely methylation state in 100-bp windows by fitting beta distributions to these samples. The modes of the most likely beta distributions were used as our final methylation calls.
We assessed Batman's quantitative performance by comparing the Batman-analyzed MeDIP-chip data with bisulfite-PCR sequencing, a technique that allows DNA methylation measurements at individual CpG sites. We considered 667 bisulifte-PCR amplicons (spanning a wide range of CpG densities) from the Human Epigenome Project (HEP) 18 that overlapped 1,481 50-mer probes in our microarray. The HEP bisulifte-PCR amplicons were generated from sperm samples different from those used in our MeDIP-chip experiments. Figure 2a shows a different version of the Batman calibration plot in which the MeDIP-chip log 2 -ratios have been colored according to HEP methylation levels, confirming that the calibration system we use provides a very good fit to the methylated section of the data. Figure 2b shows how Batman transforms LOESS-normalized log 2 -ratios into more quantitative results (R 2 ¼ 0.82, Pearson's) by increasing the dynamic range in low-CpG regions (although some noise still remains in this region). This is a significant improvement over using (i) LOESSnormalized log 2 -ratios (in a 100-bp window centered around a 50-mer) probe that overlaps a HEP amplicon, (R 2 ¼ 0.46, Pearson's correlation coefficient)), (ii) simple averaging of the LOESS-normalized log 2 -ratios for all probes within a 500-bp window (R 2 ¼ 0.55, Pearson's correlation coefficient) or (iii) averaging of the LOESSnormalized log 2 -ratios for all probes within a 500-bp window and then dividing by the number of CpG sites within that window (R 2 ¼ 0.50, Pearson's correlation coefficient). There are two likely explanations for the poor performance of the last method: firstly, as it isn't a Bayesian method, there is no propagation of uncertainty (consequently noise in low-CpG regions is amplified), and secondly, the CpG influence is not necessarily the same for all probes in a 500-bp window. Batman addresses both of these issues. It is important to note that, in addition to estimating methylation levels in CpG-poor regions, Batman also effectively estimates methylation levels in CpGdense methylated regions. Of the 667 bisulfite-PCR amplicons mentioned above, 15 are classified as CpG islands in the Ensembl genome browser and display 480% methylation in the HEP. Batman Supplementary  Fig. 3 and Supplementary Table 3 online).
We also tested Batman's performance on an independently generated MeDIP-chip data set 27 . Weber et al. (2007) analyzed MeDIP profiles of B16,000 promoters in human WI38 primary lung fibroblasts using highdensity oligonucleotide arrays. We applied Batman to their MeDIP-chip data and analyzed promoters for which they also generated bisulfite-sequencing data (Supplementary Fig. 4 online) . Batman was able to estimate absolute methylation levels over a wide range of CpG densities including low CpG density promoters (or LCPs 27 , CpG o/e B0.2).
As there is still a degree of noise in the Batman results, we also show the mean Batman score for all regions with a given bisulfite methylation state (Fig. 2c) , demonstrating Batman's output correlates almost linearly with the bisulfite results. It should be noted that Batman rarely outputs very extreme values (close to 0% or 100%) from MeDIP-chip data. This is a consequence of the Bayesian approach taken by Batman: each methylation call is associated with some degree of uncertainty, as represented by a credible interval. As methylation levels o0% or 4100% are meaningless, the entire credible interval must fit within a 0-100% scale. This means that the most credible estimates of methylation state are displaced away from the extremes. In principle, it would be possible to correct for this 'compression' artifact by reading values off a curve (Fig. 2c) . However, this transformation would complicate any consideration of the uncertainties attached to each methylation estimate. As we do not find the compression to be a major problem when working with MeDIP-chip data, we report the output of the Bayesian model directly.
A human methylome generated using MeDIP-seq Recently, next-generation sequencing technologies have emerged as powerful tools for whole-genome profiling of epigenetic modifications. They have been combined with chromatin immunoprecipitation (ChIP-Seq) 34, 35 for the analysis of histone modifications in human and mouse and with bisulfite sequencing (BS-seq 19 ) to elucidate the DNA methylation profile of the 120-Mb Arabidopsis genome. Inspired by these approaches, we combined MeDIP with next-generation sequencing-an approach we term MeDIP-seq-to generate a high-resolution whole-genome DNA methylation profile (DNA methylome) of a mammalian genome and show that Batman can also be used to estimate absolute DNA methylation levels from MeDIP-seq DNA methylome data.
We performed a second MeDIP on one of the sperm samples used in our MeDIP-chip experiments (sample SP3, Supplementary Table 1 ). The immunoprecipitated fraction was then subjected to next-generation sequencing using an Illumina Genome Analyzer. We obtained B34.2 million single-and B12 million paired-end reads that were mapped to the human genome using the Maq software (http://maq.sf.net/ and Li et al., data not shown). Only high-quality read placements (Maq quality Z 10) were used, resulting in a total of B26.5 million reads meeting this criterion. To maximize coverage, given the relatively short reads generated by the Illumina Genome Analyzer, we performed a smoothing step on the data by extending each paired-end read to a constant length of 500 bp and representing each singleton read as a 500-bp block centered around the single read's mapping position. We do not expect this step to be necessary if longer fragments are selected.
Assessment of the mapping quality revealed a degree of nonuniformity. For instance, there is a secondary peak of windows with extremely low mapping quality (o10% of reads map with q Z 10) (Fig. 3a) . Many of these windows occur in large (megabase-scale) blocks. Investigation of representative examples suggests that they correspond with known duplications/structural variations in the human genome 32 (data not shown). We chose to mask out these (a) MeDIP-seq read depth (that is, the number of confidently placed reads overlapping a given point in the genome) for points overlapping HEP amplicons, plotted against total CpG coupling factor. Points are colored according to sperm DNA methylation (yellow-blue represents 0-100% methylation), as measured in HEP 16 .
(b) MeDIP-seq versus sperm bisulfite-PCR sequencing data from HEP 16 . 100 bp MeDIP-seq tiles are plotted against 1,322 overlapping HEP bisulfite-PCR amplicons. As in Figure 2b , HEP methylation values for all CpGs that overlapped any given 100-bp MeDIP-seq tile were averaged, and all 100-bp windows were required to have at least two HEP scores (that is, either data from the top and bottom strand for a single CpG site, or at least two CpG sites) that differed by o50%. The purple-yellow (0-30) color bar on the right of each figure shows the total CpG coupling factor for each 100-bp tile. The same data stratified by CpG density is displayed in Supplementary Fig. 4 online. 
A N A L Y S I S
regions, representing B75 Mb of the genome. These regions are not included in the MeDIP-seq web display or any of our subsequent analyses. Such regions are also likely to be difficult to handle using other DNA methylation profiling strategies. We then assessed whether sufficient read-depth had been obtained, as an insufficient number of reads would result in some parts of the genome being incorrectly called unmethylated. We therefore considered regions of the genome scored by MeDIP-chip as methylated and calculated the fraction of these regions that were covered by either the complete set of MeDIP-seq reads or by randomly chosen subsets of various sizes (Fig. 3b) . This shows that our MeDIP-seq data set covers 497% of methylated regions. We consider this coverage to be good, supported by subsequent comparisons of our MeDIP-seq results with bisulfite-PCR sequencing data from the HEP (described below). A further increase in read depth would possibly yield slightly more accurate results, but any such improvement would be subject to rapidly diminishing returns.
Batman analysis of MeDIP-seq
Two slight modifications to the MeDIP-chip version of Batman were required when handling MeDIP-seq data. First, as the read-out we use for MeDIP-seq is an absolute read density (which we sampled at arbitrary 50-bp intervals along the genome) rather than a log 2 -ratio, a different model was required. Based on visual inspection of the MeDIP-seq data (Fig. 4a) , we used a polynomial model of order 2 instead of the linear model used for MeDIP-chip (Figs. 1b and 2a) . Second, the Gaussian error model was no longer appropriate (as the read density can never fall below zero), but a rectified Gaussian model could be used in a closely analogous manner. Following these two modifications, inference was performed as described above. We selected an output resolution of 100 bp as a good compromise between fast computation and high resolution. This resolution is likely to be sufficient for many applications, as the methylation status of CpG sites within o1,000 bp is significantly correlated (e.g., B75% for r100 bp). Initially, this process gave results covering the entire human genome except for assembly gaps and regions containing no CpGs. However, as the short reads from the Illumina Genome Analyzer cannot be unambiguously mapped onto some repetitive parts of the genome, we expect Batman to undercall the methylation levels of the interior parts of large repeats. In recognition of this, we discarded all Batman results overlapping 500-bp genomic tiles with 450% repeat coverage. Comparison of the Batman-analyzed MeDIPseq results with sperm data from the HEP revealed a strong overall correlation (R 2 ¼ 0.85) (Fig. 4b and Supplementary Fig. 5 online) .
Our MeDIP-seq data provides high-resolution, quantitative coverage for B90% of all CpG sites within CpG islands, promoters and other regulatory sequences, exons and introns, and B60% of all CpGs in the human genome (Fig. 5a ). This represents a B20Â improvement in coverage over existing methods. The use of paired-end sequencing allowed us to measure DNA methylation levels of some small repeat-element families. Several recent studies on human 36, 37 and mouse 38, 39 have reported epigenetic variability at repeat elements, and these could have phenotypic consequences. Furthermore, epigenetic silencing of repeat elements is thought to be critical for genomic integrity 40 . MeDIP-seq thus provides a means of analyzing such repeat elements in future DNA methylome studies. Consistent with previous observations from genome-wide studies 18, 27 , Batman analysis of the MeDIP-seq data reveals that promoters display an inverse correlation between CpG density and methylation ( Supplementary Fig. 6 online) ; CpG islands are predominantly unmethylated; a significant proportion of sites recognized by CTCF, a DNA binding protein involved in insulator activity, are unmethylated 41 ; and most other regions of the genome are methylated. Our Batman-analyzed MeDIP-seq data (and the MeDIP-chip data) are freely accessible via the Ensembl Genome Browser (Fig. 5b and http://www.ensembl.org/), representing a useful resource for the scientific community.
DISCUSSION
Unraveling the complexities of the epigenome is a very important objective, and recent years have seen the development of several strategies for genome-wide analysis of epigenetic marks, including DNA methylation. One of the principal challenges now is to develop more powerful analytical tools to interpret the vast amounts of data that continue to be generated.
Here, we have reported the development and validation of Batman, a cross-platform algorithm for the quantitative analysis of MeDIP data generated using either arrays (MeDIP-chip) or next-generation sequencing technologies (MeDIP-seq, representing a high-resolution DNA methylome of a mammalian genome). Batman, combined with MeDIP-chip or MeDIP-seq, estimates absolute methylation levels over A N A L Y S I S a wide range of CpG densities. This is a very useful property for DNA methylome analyses, as it will allow more effective profiling, including CpG-poor regions that have traditionally been overlooked in most DNA methylome studies. Furthermore, estimation of absolute DNA methylation levels will facilitate cross-platform comparisons. Although several strategies now exist for DNA methylation profiling, there are, to the best of our knowledge, only two others that compare with combining Batman with MeDIP-chip or MeDIP-seq in terms of genomic coverage and quantitative performance. The first, comprehensive high-throughput arrays for relative methylation (CHARM), combines a tiling-array design strategy with statistical procedures that average information from neighboring genomic locations 42 . The authors applied CHARM to an assay involving digesting DNA with McrBC, which restricts methylated DNA (recognition sequence R m C(N) 55-103 R m C). The enzyme is used on size-selected (1.5-4.0 kb) DNA to fractionate unmethylated DNA after digestion, which is co-hybridized on arrays with DNA similarly processed but not cut with the enzyme. Although CHARM correlates well with bisulfite conversion-based data (R 2 ¼ 0.76) 42 , it is not a 'stand-alone' algorithm but rather a strategy that requires the use of a particular array design. Moreover, it is unclear whether it can be adapted to nextgeneration sequencing technologies. It does not estimate absolute DNA methylation levels and suffers to some degree in the ability to discriminate highly methylated from highly unmethylated CpG islands 42 . Interestingly, the authors also tested MeDIP-chip and concluded that it cannot be used to analyze CpG-poor regions 42 . Our results show that combining MeDIP with Batman can provide absolute DNA methylation levels across a range of CpG densities (including CpG-poor regions) from arrays or next-generation sequencing.
Another recently reported approach, BS-seq, was used to delineate a DNA methylome for the B120-Mb Arabidopsis genome 19 . BS-seq has the ability to provide single bp-resolution DNA methylation profiles, which is indeed a very useful property. However, at current sequencing costs, such an approach is still prohibitively expensive to analyze larger genomes such as the human, which is B25Â bigger than the Arabidopsis genome. Based on our results, we estimate that B40 million paired-end reads (less than a single run of an Illumina Genome Analyzer) are sufficient to generate a high-quality mammalian methylome, whereas B3.8 Gb of sequence (which would equate to 440 million paired-end reads) was required to generate a single-base pair resolution (B20Â coverage) methylome for the B120-Mb Arabidopsis genome using BS-seq 19 . Also, even though single-CpG resolution is desirable, the fact that the methylation status of CpG sites within o1,000 bp is significantly correlated 18 (e.g., B75% for r100 bp) means that the B100 bp resolution is suitable for many applications.
Although Batman in its present form performs well, we see opportunities for future development of MeDIP-post-processing platforms, especially with regard to the use of sequencing technologies. In particular, when analyzing paired-end MeDIP-seq data, it should be possible to take advantage of the exact mapping positions of each read, rather than summarizing the data as a set of read-depth samples, thereby improving the resolution. Also, it would be interesting to apply Batman to the analysis of Arabidopsis MeDIP data. Although both CpG and non-CpG methylation is found in Arabidopsis 22,26 , gene bodies contain predominantly the former, and therefore, it should be possible to use Batman for the analysis of genic regions.
In the near future, the integration of (epi)genomic and functional approaches is going to be crucial for elucidating the biological role of DNA methylation. The need for such an integrated approach is also evident from the recently announced National Institutes of Health Epigenome Roadmap Initiative calling for mapping of reference DNA methylation profiles on an unprecedented scale (http://nihroadmap. nih.gov/epigenomics/). Combining the Batman algorithm with MeDIP-chip or MeDIP-seq should provide cost-effective strategies for quantitative, high-resolution DNA methylome analysis and will contribute toward elucidating the role of the epigenome in health and disease. Methylated DNA immunoprecipitation. MeDIP was performed using a previously published protocol 20 , but we also included a ligation-mediated PCR (LM-PCR) step 43 to amplify the material (the LM-PCR step was not performed for MeDIP-seq). Hybridizations of pre-and post-LM-PCR samples on custom tile-path arrays (2 kb resolution) for the human MHC showed that the LM-PCR did not introduce significant bias ( Supplementary Fig. 1) . A detailed protocol is provided in the Supplementary Methods online.
METHODS
Custom oligonucleotide array design and pre-Batman processing. Our microarray consists of 382,178 50-bp probes. Although we aimed to target all annotated TSSs and nonpromoter CpG islands (CGIs), we were unable to design suitable unique probes for 18% of the TSSs and 28% of nonpromoter CGIs. The array also contained 50-mer probes tiled at B100-bp density across the entire human MHC, and promoters and nonpromoter CpG islands on the X-and Y-chromosomes. Analyses of these regions will be presented elsewhere. The array was originally designed using the NCBI build 35 version of the human genome assembly, but then mapped to NCBI build 36 using Exonerate 44 . To be mapped, probes were required to align full length and without gaps or mismatches. Probes that aligned more than once to the NCBI36 sequence were removed from the analysis. Tiled regions were defined by clustering uniquely mapped probes within 200 bp of one another. Singleton probes were discarded. The tiled regions were then divided into 500-bp ROIs. After hybridization (performed by Nimblegen using their standard conditions), arrays were LOESS-normalized using custom R-scripts before Batman anlaysis of the resulting log 2 ratios.
Illumina Genome Analyzer sequencing. Based on the manufacturer's recommended protocol, we nebulized 10 mg sperm DNA (SP3 in Supplementary  Table 1 ) with compressed nitrogen for 6 min at 32 p.s.i., giving fragments of o800 bp. We then end repaired, phosphorylated and A-tailed the fragmented DNA and ligated Illumina paired end adapters to fragments. Of this, we used B1 mg of adaptor-ligated DNA for subsequent MeDIP enrichment (performed as described above but without the LM-PCR step). Because the quantity of DNA obtained after MeDIP was low (B30 ng), we deviated from the standard Illumina protocol and amplified the sample using Illumina paired-end PCR primers before gel electrophoresis and size-selecting libraries. We excised bands from the gel to produce libraries with insert sizes of 85-160 bp and quantified these libraries using an Agilent Bioanalyzer 2100. We prepared paired-end flowcells with 3.2 pM DNA (using two-primer chemistry) using the manufacturer's recommended protocol and sequenced for 36 cycles on an Illumina genome analyzer fitted with a paired-end module. The reads were mapped onto the human genome reference sequence using the high-performance alignment software 'maq' (http://maq.sf.net/) before Batman analysis.
Statistics. All correlation coefficients were computed using Pearson's productmoment formula. All credible intervals were estimated by bootstrapping. All other statistical procedures related to Batman are described in the main text.
Accession codes. ArrayExpress: MeDIP-chip data have been deposited with number E-TABM-445; MeDIP-seq data have been deposited with number E-TABM-482.
Note: Supplementary information is available on the Nature Biotechnology website.
